NAD+ and NAFLD - Caution, Causality, and Careful Optimism

Research output: Contribution to journalJournal articlepeer-review

Standard

NAD+ and NAFLD - Caution, Causality, and Careful Optimism. / Dall, Morten; Hassing, Anna S; Treebak, Jonas T.

In: The Journal of Physiology, Vol. 600, No. 5, 2022, p. 1135-1154.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Dall, M, Hassing, AS & Treebak, JT 2022, 'NAD+ and NAFLD - Caution, Causality, and Careful Optimism', The Journal of Physiology, vol. 600, no. 5, pp. 1135-1154. https://doi.org/10.1113/JP280908

APA

Dall, M., Hassing, A. S., & Treebak, J. T. (2022). NAD+ and NAFLD - Caution, Causality, and Careful Optimism. The Journal of Physiology, 600(5), 1135-1154. https://doi.org/10.1113/JP280908

Vancouver

Dall M, Hassing AS, Treebak JT. NAD+ and NAFLD - Caution, Causality, and Careful Optimism. The Journal of Physiology. 2022;600(5):1135-1154. https://doi.org/10.1113/JP280908

Author

Dall, Morten ; Hassing, Anna S ; Treebak, Jonas T. / NAD+ and NAFLD - Caution, Causality, and Careful Optimism. In: The Journal of Physiology. 2022 ; Vol. 600, No. 5. pp. 1135-1154.

Bibtex

@article{5228d30db9824686bcb6163a6030d164,
title = "NAD+ and NAFLD - Caution, Causality, and Careful Optimism",
abstract = "The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, and new treatments are direly needed. Nicotinamide adenine dinucleotide (NAD+ ) has been proposed as a potential target to prevent and reverse NAFLD. NAD+ is an important redox factor for energy metabolism and is used as a substrate by a range of enzymes, including sirtuins (SIRT), which regulates histone acetylation, transcription factor activity and mitochondrial function. NAD+ is also a precursor for reduced nicotinamide adenine dinucleotide phosphate (NADPH), which is an important component of the antioxidant defense system. NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are available as over-the-counter dietary supplements, and oral supplementation with these precursors increases hepatic NAD+ levels and prevent hepatic lipid accumulation in pre-clinical models of NAFLD. Moreover, NAD+ precursors were found to improve hepatic mitochondrial function and decrease oxidative stress in pre-clinical NAFLD models. NAD+ repletion also prevents NAFLD progression to non-alcoholic steatohepatitis (NASH), as NAD+ precursor supplementation is associated with decreased hepatic stellate cell activation, and decreased fibrosis. However, initial clinical trials have only shown modest effects when NAD+ precursors were administrated to people with obesity. We review the available pre-clinical investigations of NAD+ supplementation for targeting NAFLD, and discuss how data from the first clinical trials can be reconciled with observations from preclinical research. This article is protected by copyright. All rights reserved.",
author = "Morten Dall and Hassing, {Anna S} and Treebak, {Jonas T}",
note = "This article is protected by copyright. All rights reserved.",
year = "2022",
doi = "10.1113/JP280908",
language = "English",
volume = "600",
pages = "1135--1154",
journal = "The Journal of Physiology",
issn = "0022-3751",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - NAD+ and NAFLD - Caution, Causality, and Careful Optimism

AU - Dall, Morten

AU - Hassing, Anna S

AU - Treebak, Jonas T

N1 - This article is protected by copyright. All rights reserved.

PY - 2022

Y1 - 2022

N2 - The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, and new treatments are direly needed. Nicotinamide adenine dinucleotide (NAD+ ) has been proposed as a potential target to prevent and reverse NAFLD. NAD+ is an important redox factor for energy metabolism and is used as a substrate by a range of enzymes, including sirtuins (SIRT), which regulates histone acetylation, transcription factor activity and mitochondrial function. NAD+ is also a precursor for reduced nicotinamide adenine dinucleotide phosphate (NADPH), which is an important component of the antioxidant defense system. NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are available as over-the-counter dietary supplements, and oral supplementation with these precursors increases hepatic NAD+ levels and prevent hepatic lipid accumulation in pre-clinical models of NAFLD. Moreover, NAD+ precursors were found to improve hepatic mitochondrial function and decrease oxidative stress in pre-clinical NAFLD models. NAD+ repletion also prevents NAFLD progression to non-alcoholic steatohepatitis (NASH), as NAD+ precursor supplementation is associated with decreased hepatic stellate cell activation, and decreased fibrosis. However, initial clinical trials have only shown modest effects when NAD+ precursors were administrated to people with obesity. We review the available pre-clinical investigations of NAD+ supplementation for targeting NAFLD, and discuss how data from the first clinical trials can be reconciled with observations from preclinical research. This article is protected by copyright. All rights reserved.

AB - The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, and new treatments are direly needed. Nicotinamide adenine dinucleotide (NAD+ ) has been proposed as a potential target to prevent and reverse NAFLD. NAD+ is an important redox factor for energy metabolism and is used as a substrate by a range of enzymes, including sirtuins (SIRT), which regulates histone acetylation, transcription factor activity and mitochondrial function. NAD+ is also a precursor for reduced nicotinamide adenine dinucleotide phosphate (NADPH), which is an important component of the antioxidant defense system. NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are available as over-the-counter dietary supplements, and oral supplementation with these precursors increases hepatic NAD+ levels and prevent hepatic lipid accumulation in pre-clinical models of NAFLD. Moreover, NAD+ precursors were found to improve hepatic mitochondrial function and decrease oxidative stress in pre-clinical NAFLD models. NAD+ repletion also prevents NAFLD progression to non-alcoholic steatohepatitis (NASH), as NAD+ precursor supplementation is associated with decreased hepatic stellate cell activation, and decreased fibrosis. However, initial clinical trials have only shown modest effects when NAD+ precursors were administrated to people with obesity. We review the available pre-clinical investigations of NAD+ supplementation for targeting NAFLD, and discuss how data from the first clinical trials can be reconciled with observations from preclinical research. This article is protected by copyright. All rights reserved.

U2 - 10.1113/JP280908

DO - 10.1113/JP280908

M3 - Journal article

C2 - 33932956

VL - 600

SP - 1135

EP - 1154

JO - The Journal of Physiology

JF - The Journal of Physiology

SN - 0022-3751

IS - 5

ER -

ID: 261110327